E

Electromed

Designs and markets airway clearance devices

Senior Financial Analyst

Full-TimePosted on 10/20/2026
$95k - $130k/yr+ Employee bonus
Senior
Bachelor's
New Prague, MN, USA
HybridMust be within commuting distance of New Prague, Minnesota. Flexible hybrid/remote work options are available.
Finance & BankingCorporate Finance & FP&A

About the job

Requirements
  • A bachelor's degree in accounting, finance, or economics is required.
  • Strong technical knowledge of Generally Accepted Accounting Principles and Sarbanes-Oxley is required to ensure the accuracy and integrity of GAAP financials filed with the Securities and Exchange Commission.
  • Advanced Microsoft Excel proficiency is required.
  • Strong critical-thinking skills are required to solve complex challenges.
  • Attention to detail and the ability to see the big picture are required.
  • Excellent verbal and written communication skills are required.
  • Adaptability and flexibility are required.
  • Openness to coaching is required.
  • Must be based within commuting distance of New Prague, Minnesota.
Responsibilities
  • Partner with the Director of FP&A and Sales Operations to develop detailed financial models and analysis across all business areas, including long-range planning, annual budgeting, revenue, costing, operating expenses, balance sheet items, and cash flow.
  • Identify process-improvement opportunities, recommend solutions, and drive implementation across finance and accounting processes.
  • Perform ad hoc projects in collaboration with the Director of FP&A and Sales Operations and other company leaders as relevant.
  • Maintain and improve travel and expense reporting, including annual Sunshine Act reporting.
  • Assist monthly with inventory and cost-of-goods-sold journal entries, financial statements, and financial reporting for quarterly and annual filings.
  • Enter and analyze costs and variances for material purchases and manufacturing costs.
  • Assist in period-end close processes, including developing analysis and support for key entries and preparing accurate, timely monthly reconciliations in accordance with GAAP and SEC reporting requirements.
  • Support external audits by interacting with external auditors, preparing supporting schedules, gathering information, and providing analysis as requested.
  • Support physical inventories and the plants' cycle-count program.
Desired Qualifications
  • CPA is preferred.
  • A public accounting background is preferred.

About the company

Electromed, Inc. designs, manufactures, and markets medical devices that provide airway clearance therapy. Its flagship product, the SmartVest Airway Clearance System, uses high frequency chest wall oscillation (HFCWO) to help people clear excess mucus from the lungs, aiding those with impaired airway clearance. The system is designed for home and clinical use, delivering oscillating pressure to the chest to loosen and move mucus so it can be coughed out. The company differentiates itself by focusing specifically on airway clearance technology and offering a hands-on commitment to service, framed by its mission to help people breathe better and live more active, fulfilling lives. Electromed’s goal is to make life’s important moments possible—one breath at a time.

Company Size

201-500

Company Stage

IPO

Headquarters

New Prague, Minnesota

Founded

1992

Get referred to Electromed

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Fiscal 2026 revenue hit $73.8 million, up 15.3%, with record operating income.
  • Q4 FY2026 revenue rose 11.6% to $19.4 million; net income jumped 54.3%.
  • Triple Down on Bronchiectasis generated two million impressions and 65,000 visits.

What critics are saying

  • BMO's $10 million revolver matures December 16, 2026, forcing refinancing.
  • A future cybersecurity incident can interrupt claims processing and cash collection.
  • SmartVest concentration makes any adoption slowdown existential for Electromed.

What makes Electromed unique

  • SmartVest patents and trademarks defend Electromed's airway-clearance technology.
  • Eighty-six percent of covered U.S. lives were under contract by May 2026.
  • Fifteen straight quarters of revenue and profit growth show durable execution.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Unlimited Paid Time Off
  • 401(k) Company Match
  • Health Insurance
  • Health Savings Account/Flexible Spending Account
  • Disability Insurance
  • Parental Leave
  • Wellness Program
  • Training Programs
  • Professional Development Budget
  • Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

2%

2 year growth

2%
Yahoo Finance
Aug 24th, 2026
Electromed Q4 2026 earnings on 25 August — GF Value sees 26% downside

Electromed Inc (ELMD) is scheduled to release its Q4 2026 earnings on 25 August 2026. Analysts expect quarterly revenue of $19.33 million and earnings of $0.32 per share. For the full year 2026, revenue is forecast at $73.60 million with earnings of $1.22 per share. These estimates have remained unchanged over the past 90 days. In the previous quarter, Electromed beat revenue expectations by 6.04% and earnings estimates by 44.03%, posting actual revenue of $18.58 million and earnings of $0.35 per share. The stock rose 25.11% following the results. Three analysts have set an average one-year price target of $40.33, suggesting 2.24% upside from the current price of $39.45. However, GuruFocus estimates a fair value of $29.08, implying 26.29% downside. The average brokerage recommendation is "outperform".

Business Wire
May 12th, 2026
Electromed reports record Q3 revenue of $18.6M, up 18%, with net income rising 59% to $3M

Electromed, a Minnesota-based airway clearance technology company, reported record financial results for its fiscal 2026 third quarter ended March 31. Net revenues increased 18.4% to $18.6 million, driven by an 18.6% rise in its core homecare market. Operating income surged 76.0% to a record $3.8 million, representing 20.3% of net revenues. Net income reached $3.0 million, or $0.35 per diluted share, up 58.8% year-over-year. The results marked Electromed's 14th consecutive quarter of year-over-year revenue and profit growth. The company ended the quarter with $17.0 million in cash, $28.3 million in accounts receivable, and no debt. CEO Jim Cunniff cited strategic investments in sales teams and 86% coverage of US lives under contract as positioning the company for continued growth.

Business Wire
Feb 10th, 2026
Electromed reports record Q2 revenue of $18.9M, up 16.3%, with net income rising 40.3% to $2.8M

Electromed, a leader in airway clearance technologies, reported record financial results for its fiscal 2026 second quarter ended 31 December 2025. Net revenues increased 16.3% to $18.9 million, driven by an 18.4% rise in its core homecare market. Operating income reached a record $3.6 million, up 42.4% year-over-year, whilst operating margin improved to 19.2% of net revenues. Net income rose 40.3% to $2.8 million, or $0.32 per diluted share. The company repurchased $2.8 million of common stock at an average price of $26.16 per share during the quarter and ended with $13.8 million in cash and no debt. This marks Electromed's 13th consecutive quarter of year-over-year revenue and net income growth.

TradingView
Dec 18th, 2025
Electromed Signs Credit Agreement With BMO Bank

Electromed entered a new senior secured revolving credit facility with BMO Bank for $10 million, maturing December 16, 2026 at one-month Term SOFR plus 1.75%. The facility is secured by a first-priority lien on substantially all assets and includes customary and financial covenants, including a min…

The Globe and Mail
Jul 29th, 2025
Electromed, Inc. to Participate in the Canaccord Genuity 45th Annual Growth Conference

Electromed, Inc. ("Electromed" or the "Company") (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that Company management will participate in the Canaccord Genuity 45 [th] Annual Growth Conference, which will be held August 12-14, 2025 in Boston, MA.